Table 3.
Validation cohort 2 | ||||
---|---|---|---|---|
High Grade vs No-Cancer + Low-grade | ||||
Variables | Univariate | Multivariate | ||
Odds ratio (CI) | p | Odds ratio (CI) | p | |
AGE | 1.10(1.01–1.19) | .027 | 1.09(0.98–1.20) | .10 |
PSA | 1.07(0.99–1.15) | .68 | ||
miR-26b-5p | .015(.000–.60) | .25 | .018(.001–.85) | .041 |
miR-30c | .97(.90–1.04) | .34 | ||
miR-21-5p | .99(.98–1.01) | .34 | ||
miR-98-5p | .62(0.27–1.44) | .62 | ||
miR-4732-3p | 1.65(1.09–2.50) | .018 | 1.4(.87–2.27) | .17 |
Let7a-5p | .99(.97–1.01) | .40 |
Abbreviations: CI Confident Interval, p p value, PSA Prostate Specific Antigen. Data are presented as odds ratio (CI). Empty cells correspond to variables that were not measured. Baseline variables that achieved a level of significance of p < .05 in the univariate analysis were entered into multivariate models